Adamas Pharmaceuticals Inc. (NASDAQ:ADMS)’s share price fell 2.6% during mid-day trading on Thursday . The company traded as low as $15.43 and last traded at $15.43, with a volume of 100,576 shares. The stock had previously closed at $15.84.

A number of research firms have recently issued reports on ADMS. Mizuho upgraded Adamas Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note on Monday, June 13th. Cowen and Company restated a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Thursday, May 12th. JMP Securities restated a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Wednesday, June 15th. Piper Jaffray Cos. restated an “overweight” rating and issued a $44.00 price target on shares of Adamas Pharmaceuticals in a research note on Tuesday, June 14th. Finally, Noble Financial restated a “buy” rating and issued a $25.00 price target on shares of Adamas Pharmaceuticals in a research note on Tuesday, June 28th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $33.60.

The company’s market cap is $339.33 million. The company has a 50-day moving average price of $16.31 and a 200 day moving average price of $17.18.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings data on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.65) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.11. Equities analysts anticipate that Adamas Pharmaceuticals Inc. will post ($3.09) earnings per share for the current year.

In related news, SVP Natalie Mcclure sold 36,000 shares of the business’s stock in a transaction that occurred on Monday, April 18th. The shares were sold at an average price of $18.50, for a total value of $666,000.00. Following the completion of the transaction, the senior vice president now owns 21,006 shares of the company’s stock, valued at $388,611. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

A number of institutional investors have modified their holdings of ADMS. Strs Ohio increased its position in shares of Adamas Pharmaceuticals by 46.9% in the fourth quarter. Strs Ohio now owns 39,800 shares of the specialty pharmaceutical company’s stock worth $1,127,000 after buying an additional 12,700 shares during the period. Tocqueville Asset Management L.P. increased its position in shares of Adamas Pharmaceuticals by 60.0% in the fourth quarter. Tocqueville Asset Management L.P. now owns 40,000 shares of the specialty pharmaceutical company’s stock worth $1,133,000 after buying an additional 15,000 shares during the last quarter. Russell Frank Co increased its position in shares of Adamas Pharmaceuticals by 119.8% in the fourth quarter. Russell Frank Co now owns 83,773 shares of the specialty pharmaceutical company’s stock worth $2,395,000 after buying an additional 45,652 shares during the last quarter. Finally, EAM Investors LLC acquired a new position in shares of Adamas Pharmaceuticals during the fourth quarter worth about $4,006,000.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.